Actively Recruiting
Randomized Study Comparing Safety and Body Processing of MK-1406 Given as Two or Three Subcutaneous Injections in Healthy Adults
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-27
400
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare how the body processes the drug MK-1406 when given as two injections versus three injections in healthy adult participants. The study also evaluates the safety and how well participants tolerate MK-1406. It is a Phase 1 clinical trial designed to gather important early information about the drugs behavior and effects. Participants receive MK-1406 through subcutaneous injections administered either as three injections or two injections on the first day of the study. The study uses a randomized, open-label, parallel group design, meaning participants are randomly assigned to one of the two groups and both researchers and participants know which treatment is given. During the study, researchers monitor participants for up to four weeks after dosing to measure how much MK-1406 is in the blood over time and observe any side effects or injection site reactions. Participants are followed for about 43 days to record any adverse events or if they stop the study due to side effects. Safety and tolerability are carefully assessed throughout the trial.
CONDITIONS
Brief Title
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here